Literature DB >> 27833018

Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells.

Heimo Syvälä1, Pasi Pennanen2, Merja Bläuer3, Teuvo L J Tammela4, Teemu J Murtola4.   

Abstract

We evaluated the effects of simvastatin and antiandrogen enzalutamide on growth and androgen signaling in androgen-sensitive LNCaP and VCaP prostate cancer cells. Simvastatin alone abolished androgen-induced growth in both cell lines but decreased androgen receptor (AR) and prostate-specific antigen protein expression only in LNCaP, indicating that statin-induced growth inhibition is beyond AR transcriptional activity in VCaP. Combination of simvastatin and enzalutamide exerted additive growth inhibition in both cell lines accompanied with strong induction of autophagy in LNCaP. The data provide new insight into statins' effects on androgen signaling and their proposed role in enhancing androgen deprivation therapy in prostate cancer.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiandrogen; Prostate cancer; Statin

Mesh：

Substances：

Year:  2016        PMID： 27833018     DOI： 10.1016/j.bbrc.2016.11.021

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity.

Authors:  Changhong Shi; Xue Chen; Dengxu Tan
Journal:  Transl Androl Urol       Date:  2019-10

Review 2.  Statins and prostate cancer-hype or hope? The biological perspective.

Authors:  Joseph Longo; Stephen J Freedland; Linda Z Penn; Robert J Hamilton
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-06-29       Impact factor: 5.554

3.  Statin Use and the Risk of Prostate Cancer Biochemical Recurrence Following Definitive Therapy: A Systematic Review and Meta-Analysis of Cohort Studies.

Authors:  Jian-Xuan Sun; Chen-Qian Liu; Xing-Yu Zhong; Jin-Zhou Xu; Ye An; Meng-Yao Xu; Jia Hu; Zong-Biao Zhang; Qi-Dong Xia; Shao-Gang Wang
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

4.  Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC).

Authors:  Yifan Kong; Lijun Cheng; Fengyi Mao; Zhuangzhuang Zhang; Yanquan Zhang; Elia Farah; Jacob Bosler; Yunfeng Bai; Nihal Ahmad; Shihuan Kuang; Lang Li; Xiaoqi Liu
Journal:  J Biol Chem       Date:  2018-08-08       Impact factor: 5.157

5.  Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes.

Authors:  Akram Mirzaei; Sina Rashedi; Mohammad Reza Akbari; Fatemeh Khatami; Seyed Mohammad Kazem Aghamir
Journal:  J Cell Mol Med       Date:  2022-04-02       Impact factor: 5.295

6.  Protective effect of Chuquiraga spinosa Lessing associated with simvastatin on N-Nitroso-N-methylurea (NMU)-induced prostate cancer in rats.

Authors:  Jorge Luis Arroyo-Acevedo; Juan Pedro Rojas-Armas; Oscar Herrera-Calderón; Roberto Chávez-Asmat; Hugo Jesús Justil-Guerrero; Cristian Aguilar-Carranza; Edwin Enciso-Roca; Johnny Aldo Tinco-Jayo; Ricardo Ángel Yuli-Posadas; Cesar Franco-Quino; Victor Chumpitaz-Cerrate
Journal:  Onco Targets Ther       Date:  2019-08-15       Impact factor: 4.147

7.  Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.

Authors:  Hannes Neuwirt; Jan Bouchal; Gvantsa Kharaishvili; Christian Ploner; Karin Jöhrer; Florian Pitterl; Anja Weber; Helmut Klocker; Iris E Eder
Journal:  Cell Commun Signal       Date:  2020-01-24       Impact factor: 5.712

Review 8.  The Mevalonate Pathway, a Metabolic Target in Cancer Therapy.

Authors:  Borja Guerra; Carlota Recio; Haidée Aranda-Tavío; Miguel Guerra-Rodríguez; José M García-Castellano; Leandro Fernández-Pérez
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

9.  Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol.

Authors:  Aino Siltari; Jarno Riikonen; Juha Koskimäki; Tomi Pakarainen; Otto Ettala; Peter Boström; Heikki Seikkula; Andres Kotsar; Teuvo Tammela; Mika Helminen; Paavo V Raittinen; Terho Lehtimäki; Mikkel Fode; Peter Østergren; Michael Borre; Antti Rannikko; Timo Marttila; Arto Salonen; Hanna Ronkainen; Sven Löffeler; Teemu J Murtola
Journal:  BMJ Open       Date:  2022-04-29       Impact factor: 2.692

10.  Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study.

Authors:  A Auvinen; T J Murtola; A I Peltomaa; P Raittinen; K Talala; K Taari; T L J Tammela
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-03-31       Impact factor: 5.554
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.